PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070374
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070374
Pembrolizumab Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of pembrolizumab Market
The global pembrolizumab market was valued at USD 31.70 billion in 2025 and is projected to grow from USD 33.10 billion in 2026 to USD 41.10 billion by 2034, registering a CAGR of 2.74% during the forecast period. Pembrolizumab, marketed mainly as KEYTRUDA, is one of the leading immuno-oncology therapies used across several cancer types. It works by helping the immune system recognize and attack cancer cells.
The market is growing steadily due to strong clinical adoption, continued label expansions, rising use in earlier treatment settings, and increasing demand for biomarker-driven cancer therapy. North America dominated the market in 2025 with a 52.77% market share, supported by high cancer incidence, advanced oncology infrastructure, broad biomarker testing, and strong reimbursement access.
Pembrolizumab Market Trends
A key trend in the market is the growing role of immunotherapy in standard cancer care. Pembrolizumab is increasingly being used not only in advanced and metastatic cancer but also in earlier-stage and perioperative treatment settings. This wider integration is strengthening physician confidence and expanding the eligible patient base.
In June 2025, Merck received U.S. FDA approval for KEYTRUDA in PD-L1 positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant and adjuvant treatment, showing its deeper role in structured cancer treatment pathways.
Market Drivers
The major driver of market growth is the rising global cancer burden. Increasing cases of lung, breast, colorectal, kidney, bladder, head and neck, and gynecologic cancers are driving demand for advanced systemic therapies. Pembrolizumab has approvals across multiple tumor types, which supports its broad clinical use. Growing diagnosis rates, wider biomarker testing, and earlier treatment intervention are also increasing the eligible treatment population.
Market Restraints
High treatment cost and reimbursement pressure remain key restraints. Pembrolizumab is a premium-priced biologic therapy, and access can be delayed in countries with strict health technology assessments and limited healthcare budgets. Reimbursement negotiations, pricing reviews, and payer restrictions can slow adoption even after regulatory approval, especially in cost-sensitive markets.
Market Opportunities
Continuous label expansion across multiple tumor types presents strong growth opportunities. Each new approval allows pembrolizumab to enter additional cancer settings, treatment lines, or patient subgroups. In February 2026, Merck announced approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, for certain adults with PD-L1-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma. This expansion supports deeper penetration in gynecologic oncology.
Market Challenges
The main challenge is rising biosimilar and patent-cliff pressure. Since pembrolizumab is a high-value biologic with large global sales, biosimilar developers are actively entering the space. Future biosimilar launches may create pricing pressure, reduce market exclusivity, and affect long-term revenue growth for the originator brand. In June 2025, Dr. Reddy's and Alvotech announced a collaboration to co-develop and commercialize a pembrolizumab biosimilar for global markets.
Segment Analysis
By product type, the market is segmented into KEYTRUDA IV and KEYTRUDA QLEX/subcutaneous pembrolizumab. KEYTRUDA IV dominated the market due to its long-established use, strong clinical familiarity, infusion-based workflows, and broad adoption across tumor types. KEYTRUDA QLEX is expected to grow at a CAGR of 20.44% due to its convenient subcutaneous administration.
By disease indication, the NSCLC segment dominated in 2025 due to high disease burden and strong pembrolizumab adoption across advanced and earlier-stage lung cancer. The others segment is projected to grow at a CAGR of 4.93%.
By age group, the adult segment dominated the market in 2025, as most approved indications and commercial use are concentrated in adult solid tumors. The pediatric segment is projected to grow at a CAGR of 6.01%.
By type, the branded segment led the market, supported by KEYTRUDA's strong global approval base and absence of marketed biosimilar competition. The biosimilar segment is expected to grow at a CAGR of 45.90% during the study period.
By therapy setting, advanced/metastatic disease dominated due to pembrolizumab's long-standing use in late-stage oncology. The early-stage/perioperative segment is projected to grow at a CAGR of 6.27%.
By route of administration, the IV segment dominated, while the SC segment is emerging with new approvals. By end user, specialty cancer clinics led the market due to strong oncology expertise, biomarker-based treatment decisions, and immunotherapy administration capabilities.
Regional Analysis
North America led the global market with USD 16.73 billion in 2025, increasing from USD 15.77 billion in 2024. The U.S. market is estimated to reach USD 15.64 billion in 2026, accounting for about 47.24% of global revenue.
Europe is projected to reach USD 7.60 billion in 2026, growing at 2.26%. The U.K. market is estimated at USD 1.38 billion, while Germany is expected to reach USD 1.70 billion in 2026.
Asia Pacific is expected to reach USD 6.24 billion in 2026, supported by a large cancer patient base and improving access to oncology medicines. China is projected at USD 2.16 billion, Japan at USD 1.46 billion, and India at USD 0.51 billion in 2026.
Latin America is set to reach USD 1.09 billion in 2026, while the GCC market is projected at USD 0.40 billion. South Africa is expected to reach USD 0.19 billion in 2026.
Competitive Landscape
The global market is highly consolidated, led by Merck & Co., Inc. Other key players include Samsung Bioepis, Sandoz, Celltrion, Shanghai Henlius Biotech, Bio-Thera Solutions, Dr. Reddy's Laboratories, Alvotech, Biocon Biologics, and Organon. Companies are focusing on regulatory approvals, biosimilar development, partnerships, and new formulations.
Conclusion
The pembrolizumab market is projected to grow from USD 31.70 billion in 2025 to USD 33.10 billion in 2026, reaching USD 41.10 billion by 2034. Growth will be supported by label expansion, rising cancer incidence, biomarker-driven therapy adoption, and subcutaneous formulation launches. However, high treatment costs, reimbursement barriers, and future biosimilar competition may moderate long-term growth.
Segmentation By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Region
By Product Type * KEYTRUDA IV
- KEYTRUDA QLEX / SC Pembrolizumab
By Disease Indication * NSCLC
- Melanoma
- HNSCC
- Urothelial Carcinoma
- RCC
- TNBC
- Gastric/GEJ/Esophageal Cancers
- Cervical Cancer
- Others
By Age Group * Pediatric
- Others
By Type * Branded
- Biosimilar
By Therapy Setting * Early-stage / Perioperative
- Advanced / Metastatic
- Others
By Route of Administration * IV
- SC
By End User * Hospitals
- Specialty Cancer Clinics
- Ambulatory Infusion Centers
- Others
By Region * North America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country)
- U.S.
- Canada
- Europe (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. New Product Launches, By Key Players
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
- 4.3. Regulatory & Reimbursement Scenario, By Key Countries/Regions
- 4.4. Pipeline Analysis, By Key Players
5. Global Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. KEYTRUDA IV
- 5.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. NSCLC
- 5.2.2. Melanoma
- 5.2.3. HNSCC
- 5.2.4. Urothelial Carcinoma
- 5.2.5. RCC
- 5.2.6. TNBC
- 5.2.7. Gastric/GEJ/Esophageal Cancers
- 5.2.8. Cervical Cancer
- 5.2.9. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Biosimilar
- 5.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 5.5.1. Early-stage / Perioperative
- 5.5.2. Advanced / Metastatic
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Route of Administration
- 5.6.1. IV
- 5.6.2. SC
- 5.7. Market Analysis, Insights and Forecast - By End User
- 5.7.1. Hospitals
- 5.7.2. Specialty Cancer Clinics
- 5.7.3. Ambulatory Infusion Centers
- 5.7.4. Others
- 5.8. Market Analysis, Insights and Forecast - Region
- 5.8.1. North America
- 5.8.2. Europe
- 5.8.3. Asia Pacific
- 5.8.4. Latin America
- 5.8.5. Middle East & Africa
6. North America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. KEYTRUDA IV
- 6.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. NSCLC
- 6.2.2. Melanoma
- 6.2.3. HNSCC
- 6.2.4. Urothelial Carcinoma
- 6.2.5. RCC
- 6.2.6. TNBC
- 6.2.7. Gastric/GEJ/Esophageal Cancers
- 6.2.8. Cervical Cancer
- 6.2.9. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Biosimilar
- 6.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 6.5.1. Early-stage / Perioperative
- 6.5.2. Advanced / Metastatic
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Route of Administration
- 6.6.1. IV
- 6.6.2. SC
- 6.7. Market Analysis, Insights and Forecast - By End User
- 6.7.1. Hospitals
- 6.7.2. Specialty Cancer Clinics
- 6.7.3. Ambulatory Infusion Centers
- 6.7.4. Others
- 6.8. Market Analysis, Insights and Forecast - By Country
- 6.8.1. U.S.
- 6.8.2. Canada
7. Europe Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. KEYTRUDA IV
- 7.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. NSCLC
- 7.2.2. Melanoma
- 7.2.3. HNSCC
- 7.2.4. Urothelial Carcinoma
- 7.2.5. RCC
- 7.2.6. TNBC
- 7.2.7. Gastric/GEJ/Esophageal Cancers
- 7.2.8. Cervical Cancer
- 7.2.9. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Biosimilar
- 7.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 7.5.1. Early-stage / Perioperative
- 7.5.2. Advanced / Metastatic
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Route of Administration
- 7.6.1. IV
- 7.6.2. SC
- 7.7. Market Analysis, Insights and Forecast - By End User
- 7.7.1. Hospitals
- 7.7.2. Specialty Cancer Clinics
- 7.7.3. Ambulatory Infusion Centers
- 7.7.4. Others
- 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.8.1. U.K.
- 7.8.2. Germany
- 7.8.3. France
- 7.8.4. Italy
- 7.8.5. Spain
- 7.8.6. Scandinavia
- 7.8.7. Rest of Europe
8. Asia Pacific Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. KEYTRUDA IV
- 8.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. NSCLC
- 8.2.2. Melanoma
- 8.2.3. HNSCC
- 8.2.4. Urothelial Carcinoma
- 8.2.5. RCC
- 8.2.6. TNBC
- 8.2.7. Gastric/GEJ/Esophageal Cancers
- 8.2.8. Cervical Cancer
- 8.2.9. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Biosimilar
- 8.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 8.5.1. Early-stage / Perioperative
- 8.5.2. Advanced / Metastatic
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Route of Administration
- 8.6.1. IV
- 8.6.2. SC
- 8.7. Market Analysis, Insights and Forecast - By End User
- 8.7.1. Hospitals
- 8.7.2. Specialty Cancer Clinics
- 8.7.3. Ambulatory Infusion Centers
- 8.7.4. Others
- 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.8.1. China
- 8.8.2. Japan
- 8.8.3. India
- 8.8.4. Southeast Asia
- 8.8.5. Australia
- 8.8.6. Rest of Asia Pacific
9. Latin America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. KEYTRUDA IV
- 9.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. NSCLC
- 9.2.2. Melanoma
- 9.2.3. HNSCC
- 9.2.4. Urothelial Carcinoma
- 9.2.5. RCC
- 9.2.6. TNBC
- 9.2.7. Gastric/GEJ/Esophageal Cancers
- 9.2.8. Cervical Cancer
- 9.2.9. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Biosimilar
- 9.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 9.5.1. Early-stage / Perioperative
- 9.5.2. Advanced / Metastatic
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Route of Administration
- 9.6.1. IV
- 9.6.2. SC
- 9.7. Market Analysis, Insights and Forecast - By End User
- 9.7.1. Hospitals
- 9.7.2. Specialty Cancer Clinics
- 9.7.3. Ambulatory Infusion Centers
- 9.7.4. Others
- 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.8.1. Brazil
- 9.8.2. Mexico
- 9.8.3. Rest of Latin America
10. Middle East & Africa Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. KEYTRUDA IV
- 10.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. NSCLC
- 10.2.2. Melanoma
- 10.2.3. HNSCC
- 10.2.4. Urothelial Carcinoma
- 10.2.5. RCC
- 10.2.6. TNBC
- 10.2.7. Gastric/GEJ/Esophageal Cancers
- 10.2.8. Cervical Cancer
- 10.2.9. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Biosimilar
- 10.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 10.5.1. Early-stage / Perioperative
- 10.5.2. Advanced / Metastatic
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Route of Administration
- 10.6.1. IV
- 10.6.2. SC
- 10.7. Market Analysis, Insights and Forecast - By End User
- 10.7.1. Hospitals
- 10.7.2. Specialty Cancer Clinics
- 10.7.3. Ambulatory Infusion Centers
- 10.7.4. Others
- 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.8.1. GCC
- 10.8.2. South Africa
- 10.8.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck & Co., Inc.
- 11.2.2. Samsung Bioepis Co., Ltd.
- 11.2.3. Sandoz AG
- 11.2.4. Celltrion, Inc.
- 11.2.5. Shanghai Henlius Biotech, Inc.
- 11.2.6. Bio-Thera Solutions, Ltd.
- 11.2.7. Dr. Reddy's Laboratories Ltd.
- 11.2.8. Alvotech
- 11.2.9. Biocon Biologics Limited
- 11.2.10. Organon & Co.
List of Tables
- Figure 1: Global Pembrolizumab Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Pembrolizumab Market Value Share (%), by Product Type, 2025 & 2034
- Figure 3: Global Pembrolizumab Market Value Share (%), by Disease Indication, 2025 & 2034
- Figure 4: Global Pembrolizumab Market Value Share (%), by Age Group, 2025 & 2034
- Figure 5: Global Pembrolizumab Market Value Share (%), by Type, 2025 & 2034
- Figure 6: Global Pembrolizumab Market Value Share (%), by Therapy Setting, 2025 & 2034
- Figure 7: Global Pembrolizumab Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 8: Global Pembrolizumab Market Value Share (%), by End User, 2025 & 2034
- Figure 9: Global Pembrolizumab Market Value Share (%), by Region, 2025 & 2034
- Figure 10: North America Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 11: North America Pembrolizumab Market Value Share (%), by Product Type, 2025
- Figure 12: North America Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 13: North America Pembrolizumab Market Value Share (%), by Disease Indication, 2025
- Figure 14: North America Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 15: North America Pembrolizumab Market Value Share (%), by Age Group, 2025
- Figure 16: North America Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
- Figure 17: North America Pembrolizumab Market Value Share (%), by Type, 2025
- Figure 18: North America Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
- Figure 19: North America Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
- Figure 20: North America Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 21: North America Pembrolizumab Market Value Share (%), by Route of Administration, 2025
- Figure 22: North America Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
- Figure 23: North America Pembrolizumab Market Value Share (%), by End User, 2025
- Figure 24: North America Pembrolizumab Market Value (USD billion), by Country, 2025 & 2034
- Figure 25: North America Pembrolizumab Market Value Share (%), by Country, 2025
- Figure 26: Europe Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 27: Europe Pembrolizumab Market Value Share (%), by Product Type, 2025
- Figure 28: Europe Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 29: Europe Pembrolizumab Market Value Share (%), by Disease Indication, 2025
- Figure 30: Europe Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 31: Europe Pembrolizumab Market Value Share (%), by Age Group, 2025
- Figure 32: Europe Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
- Figure 33: Europe Pembrolizumab Market Value Share (%), by Type, 2025
- Figure 34: Europe Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
- Figure 35: Europe Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
- Figure 36: Europe Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 37: Europe Pembrolizumab Market Value Share (%), by Route of Administration, 2025
- Figure 38: Europe Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
- Figure 39: Europe Pembrolizumab Market Value Share (%), by End User, 2025
- Figure 40: Europe Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 41: Europe Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
- Figure 42: Asia Pacific Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 43: Asia Pacific Pembrolizumab Market Value Share (%), by Product Type, 2025
- Figure 44: Asia Pacific Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 45: Asia Pacific Pembrolizumab Market Value Share (%), by Disease Indication, 2025
- Figure 46: Asia Pacific Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 47: Asia Pacific Pembrolizumab Market Value Share (%), by Age Group, 2025
- Figure 48: Asia Pacific Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
- Figure 49: Asia Pacific Pembrolizumab Market Value Share (%), by Type, 2025
- Figure 50: Asia Pacific Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
- Figure 51: Asia Pacific Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
- Figure 52: Asia Pacific Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 53: Asia Pacific Pembrolizumab Market Value Share (%), by Route of Administration, 2025
- Figure 54: Asia Pacific Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
- Figure 55: Asia Pacific Pembrolizumab Market Value Share (%), by End User, 2025
- Figure 56: Asia Pacific Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 57: Asia Pacific Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
- Figure 58: Latin America Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 59: Latin America Pembrolizumab Market Value Share (%), by Product Type, 2025
- Figure 60: Latin America Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 61: Latin America Pembrolizumab Market Value Share (%), by Disease Indication, 2025
- Figure 62: Latin America Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 63: Latin America Pembrolizumab Market Value Share (%), by Age Group, 2025
- Figure 64: Latin America Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
- Figure 65: Latin America Pembrolizumab Market Value Share (%), by Type, 2025
- Figure 66: Latin America Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
- Figure 67: Latin America Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
- Figure 68: Latin America Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 69: Latin America Pembrolizumab Market Value Share (%), by Route of Administration, 2025
- Figure 70: Latin America Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
- Figure 71: Latin America Pembrolizumab Market Value Share (%), by End User, 2025
- Figure 72: Latin America Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 73: Latin America Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
- Figure 74: Middle East & Africa Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 75: Middle East & Africa Pembrolizumab Market Value Share (%), by Product Type, 2025
- Figure 76: Middle East & Africa Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 77: Middle East & Africa Pembrolizumab Market Value Share (%), by Disease Indication, 2025
- Figure 78: Middle East & Africa Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 79: Middle East & Africa Pembrolizumab Market Value Share (%), by Age Group, 2025
- Figure 80: Middle East & Africa Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
- Figure 81: Middle East & Africa Pembrolizumab Market Value Share (%), by Type, 2025
- Figure 82: Middle East & Africa Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
- Figure 83: Middle East & Africa Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
- Figure 84: Middle East & Africa Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 85: Middle East & Africa Pembrolizumab Market Value Share (%), by Route of Administration, 2025
- Figure 86: Middle East & Africa Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
- Figure 87: Middle East & Africa Pembrolizumab Market Value Share (%), by End User, 2025
- Figure 88: Middle East & Africa Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 89: Middle East & Africa Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
- Figure 90: Global Pembrolizumab Market Share (%), by Company, 2025
